While everyone seems to be occupied on developing a vaccine against COVID-19, Protinhi Therapeutics is working on another promising drug: viral inhibitors. Bernd van Buuren, CEO of the Nijmegen based biotech company, recently received a final go from Health Holland for PanCoroNed: a new collaboration between Avivia, Radboud University, Utrecht University, Leiden UMC and Protinhi for the development of viral inhibitors against COVID-19. Over the past years, Protinhi worked on means against tropical infectious diseases, such as dengue, and is now deploying this expertise against the coronavirus: “With our background and joined forces, we hope to develop a means which inhibits corona and may even prevent a future outbreak.”